Andrew J. Vickers

Active 1994–2025

Also published as
Andrew J Vickers
304
Papers
65,823
Citations
124
h-index
282
i10-index

Citations

Citations per year for Andrew J. Vickers1970: 1 citations1985: 2 citations1989: 1 citations1993: 2 citations1995: 4 citations1996: 1 citations1997: 3 citations1998: 16 citations1999: 11 citations2000: 32 citations2001: 51 citations2002: 56 citations2003: 57 citations2004: 80 citations2005: 102 citations2006: 119 citations2007: 164 citations2008: 240 citations2009: 299 citations2010: 378 citations2011: 381 citations2012: 408 citations2013: 444 citations2014: 424 citations2015: 470 citations2016: 547 citations2017: 516 citations2018: 484 citations2019: 1,738 citations2020: 2,250 citations2021: 2,064 citations2022: 1,666 citations2023: 1,156 citations2024: 2,096 citations2025: 922 citations2026: 109 citations2027: 1 citations1971–1984: no citations, so these years are not shown1986–1988: no citations, so these years are not shown1990–1992: no citations, so these years are not shown1994: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,369 citing papers, 20.8% of this breakdownChina: 2,747 citing papers, 10.7% of this breakdownUnited Kingdom: 2,300 citing papers, 8.9% of this breakdownGermany: 1,326 citing papers, 5.1% of this breakdownNetherlands: 1,303 citing papers, 5.1% of this breakdownCanada: 1,260 citing papers, 4.9% of this breakdownItaly: 1,227 citing papers, 4.8% of this breakdownAustralia: 881 citing papers, 3.4% of this breakdownFrance: 786 citing papers, 3% of this breakdownSpain: 629 citing papers, 2.4% of this breakdownSwitzerland: 567 citing papers, 2.2% of this breakdownSweden: 516 citing papers, 2% of this breakdown
0%20.8%Other 26.7%

Fields

  • Medicine73.9%
  • Biochemistry, Genetics and Molecular Biology7.9%
  • Computer Science4.8%
  • Decision Sciences2%
  • Health Professions1.8%
  • Psychology1.7%
  • Other7.9%

Topics

  • Prostate Cancer Diagnosis and Treatment4.9%
  • Prostate Cancer Treatment and Research4.2%
  • Bladder and Urothelial Cancer Treatments2.1%
  • Radiomics and Machine Learning in Medical Imaging2.1%
  • Acupuncture Treatment Research Studies1.8%
  • Complementary and Alternative Medicine Studies1.5%
  • Other83.4%

Coauthors

All papers

Open in search
  1. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration

    Authors: , , , , , , , , - Annals of Internal Medicine 2015 cited by 5,183

  2. Decision Curve Analysis: A Novel Method for Evaluating Prediction Models

    Authors: , - Medical Decision Making 2006 cited by 5,471

  3. Assessing the Performance of Prediction Models

    Authors: , , , , , , , - Epidemiology 2009 cited by 4,864

  4. A simple, step-by-step guide to interpreting decision curve analysis

    Authors: , , - Diagnostic and Prognostic Research 2019 cited by 1,060

  5. Reporting and Interpreting Decision Curve Analysis: A Guide for Investigators

    Authors: , , , , , , , - European Urology 2018 cited by 1,296

  6. Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests

    Authors: , , - BMJ 2016 cited by 1,090

  7. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers

    Authors: , , , - BMC Medical Informatics and Decision Making, BMC Medical Informatics Decis. Mak. 2008 cited by 1,441

  8. Acupuncture for Chronic Pain: Update of an Individual Patient Data Meta-Analysis

    Authors: , , , , , , , , - Journal of Pain 2017 cited by 831

  9. The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement

    Authors: , , , , , , , , , , , , , , , , - Annals of Internal Medicine 2019 cited by 432

  10. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring

    Authors: , , - Nature reviews. Cancer 2008 cited by 919

  11. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score

    Authors: , , , , , , , , , , , , , , , , - European Urology 2015 cited by 1,368

  12. Decision curve analysis to evaluate the clinical benefit of prediction models

    Authors: , - The Spine Journal 2021 cited by 349

  13. Calibration of Risk Prediction Models

    Authors: , - Medical Decision Making 2014 cited by 358

  14. Against quantiles: categorization of continuous variables in epidemiologic research, and its discontents

    Authors: , - BMC Medical Research Methodology 2012 cited by 429

  15. Analysing controlled trials with baseline and follow up measurements

    Authors: , - BMJ 2001 cited by 1,992

  16. Assessing Performance and Clinical Usefulness in Prediction Models With Survival Outcomes: Practical Guidance for Cox Proportional Hazards Models

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Per Kragh Andersen, Torben Martinussen, Maja Pohar Perme, Hein Putter, Jeremy M. G. Taylor - Annals of Internal Medicine 2022 cited by 157

  17. Transperineal Versus Transrectal Magnetic Resonance Imaging–targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - European Urology 2024 cited by 177

  18. Guidelines for Reporting of Statistics for Clinical Research in Urology

    Authors: , , , , , , , , , , , , , , , - British Journal of Urology 2018 cited by 318

  19. Limited versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial

    Authors: , , , , , , , - European Urology Oncology 2021 cited by 170

  20. Increasing value and reducing waste: addressing inaccessible research

    Authors: , , , , , , , , - The Lancet 2014 cited by 923

  21. Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit

    Authors: , , , , , , , , , - BMJ 2023 cited by 86

  22. Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death

    Authors: , , , , , , , , , , , , , , - eLife 2018 cited by 300

  23. The Brier score does not evaluate the clinical utility of diagnostic tests or prediction models

    Authors: , , - Diagnostic and Prognostic Research 2017 cited by 143

  24. Age‐adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer

    Authors: , , , , , , , - Cancer 2008 cited by 357